Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas U.S. Unit Settles Off-Label Pediatric Use Case For $7.3 Million

This article was originally published in PharmAsia News

Executive Summary

Astellas Pharma, the U.S. unit of the Japan-based drug maker, has agreed to pay a $7.3 million fine for promoting pediatric use of its Mycamine (mycafungin) drug for treating invasive fungal infections.

You may also be interested in...



UK COVID Second Wave Could Drive OTC Paracetamol And Ibuprofen Prices Back Up

Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again. 

EU Business Round-Up: Sanofi Pens Enzymatica Deal, Germany's WindStar Acquired, Ipsen's Sales Slump

Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.

Coronavirus Update: Lilly’s Antibody Plus Remdesivir Trial Abandoned

Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.

Topics

UsernamePublicRestriction

Register

ID1132046

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel